Technology, Digitalisation and Connectivity Impact in Diabetes Management

Location: STC Seminar Hall, Department of Aerospace Engineering


Date:  23rd November 2022
Time: 15:00 – 16:00
Venue: STC Seminar Hall, Dept. of Aerospace Engineering, IISc

About Company: Ypsomed founded by the brothers Willy and Peter Michel and headquartered at Burgdorf, Switzerland is a successor of their earlier company, Disetronic. Retaining the injection business from Disetronic times Ypsomed is back into insulin pump business from 2016. Ypsomed focuses on ‘ipso’-self medication making selfcare simpler and easier.

About Speaker: Dr. Sanjay Rajpal, the Country Manager of Ypsomed India Pvt Ltd, looks after India, Sri Lanka, Bangladesh and Nepal. He has an extensive 25 years of experience in health care industry. He mentors young professional in Diabetes education. Dr. Sanjay Graduated from University of Delhi and did PG Diplomain Marketing and sales Management form YMCA and Business Management from Asian Institute of Management, Philippines. He also did PG Diploma In Public Health Management after that he did PhD in Public Health Management from National Institute of Health & Family Welfare, Ministry of Health.

Having started his career with French company Servier and S, Dr. Sanjay later joined Eli Lilly and Company, BBraun, Beckton Dickinson and Dentsply successively. He has written a book on Business Etiquette & Co Authored book on Patient Centric Healthcare Practices. He also completed Certifcation in Insulin Pump Therapy from Cardiff University-UK.

Abstract: Millions of people with chronic diseases use products for self-medication purposes. Time has come to for networked devices that make self-medication easier for users. These devices, together with Smart Services, form the basis for new care and support models which help relieve the burden on the healthcare system and make it more ecient. For the treatment of diabetes, the digital ecosystem is currently making a signicant leap towards a more automated insulin therapy.

Digitalisation in Diabetes:

  • Application of digital technologies to increase therapeutic success
  • Collaboration with partners outside traditional industry boundaries
  • Creation of new mechanisms for patient interaction and stakeholder integration